1. Home
  2. CMPS vs UROY Comparison

CMPS vs UROY Comparison

Compare CMPS & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPS
  • UROY
  • Stock Information
  • Founded
  • CMPS 2020
  • UROY 2017
  • Country
  • CMPS United Kingdom
  • UROY Canada
  • Employees
  • CMPS N/A
  • UROY N/A
  • Industry
  • CMPS Biotechnology: Pharmaceutical Preparations
  • UROY
  • Sector
  • CMPS Health Care
  • UROY
  • Exchange
  • CMPS Nasdaq
  • UROY Nasdaq
  • Market Cap
  • CMPS 598.7M
  • UROY 513.2M
  • IPO Year
  • CMPS 2020
  • UROY N/A
  • Fundamental
  • Price
  • CMPS $5.31
  • UROY $3.60
  • Analyst Decision
  • CMPS Strong Buy
  • UROY Strong Buy
  • Analyst Count
  • CMPS 8
  • UROY 1
  • Target Price
  • CMPS $16.43
  • UROY $4.50
  • AVG Volume (30 Days)
  • CMPS 2.1M
  • UROY 4.2M
  • Earning Date
  • CMPS 11-04-2025
  • UROY 12-11-2025
  • Dividend Yield
  • CMPS N/A
  • UROY N/A
  • EPS Growth
  • CMPS N/A
  • UROY N/A
  • EPS
  • CMPS N/A
  • UROY N/A
  • Revenue
  • CMPS N/A
  • UROY $35,266,447.00
  • Revenue This Year
  • CMPS N/A
  • UROY $195.97
  • Revenue Next Year
  • CMPS N/A
  • UROY N/A
  • P/E Ratio
  • CMPS N/A
  • UROY N/A
  • Revenue Growth
  • CMPS N/A
  • UROY 14.29
  • 52 Week Low
  • CMPS $2.25
  • UROY $1.43
  • 52 Week High
  • CMPS $7.09
  • UROY $5.37
  • Technical
  • Relative Strength Index (RSI)
  • CMPS 41.21
  • UROY 40.56
  • Support Level
  • CMPS $5.01
  • UROY $3.43
  • Resistance Level
  • CMPS $6.01
  • UROY $3.99
  • Average True Range (ATR)
  • CMPS 0.47
  • UROY 0.26
  • MACD
  • CMPS -0.09
  • UROY -0.07
  • Stochastic Oscillator
  • CMPS 15.78
  • UROY 9.75

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.

Share on Social Networks: